Association of the Magnitude of Anti-SARS-CoV-2 Vaccine Side Effects with Sex, Allergy History, Chronic Diseases, Medication Intake, and SARS-CoV-2 Infection
Author:
Said Elias A.1, Al-Rubkhi Afnan1, Jaju Sanjay2, Koh Crystal Y.1, Al-Balushi Mohammed S.1, Al-Naamani Khalid3, Al-Sinani Siham4, Al-Busaidi Juma Z.1, Al-Jabri Ali A.1
Affiliation:
1. Department of Microbiology and Immunology, College of Medicine and Health Sciences, Sultan Qaboos University, P.O. Box 35, Muscat 123, Oman 2. Department of Family Medicine and Public Health, College of Medicine and Health Sciences, Sultan Qaboos University, P.O. Box 35, Muscat 123, Oman 3. Department of Medicine, Armed Forces Hospital, P.O. Box 726, Muscat 111, Oman 4. Oman Medical Specialty Board, P.O. Box 1948, Muscat 130, Oman
Abstract
Vaccination provides the best protection against the increasing infections of SARS-CoV-2. The magnitude and type of anti-SARS-CoV-2 vaccine side effects (SEs) depend on parameters that are not fully understood. In this cross-sectional study, the associations between different anti-SARS-CoV-2 vaccine SEs and age, sex, the presence of chronic diseases, medication intake, history of allergies, and infections with SARS-CoV-2 were investigated. Our survey used the Google platform and had 866 participants, contacted through e-mails, social media and chain referral sampling (margin of error ≈ 4.38%, 99% confidence). More than 99% of the participants received the BNT162b2 and ChAdOx1-S vaccines. Being female, having chronic diseases, taking medicines routinely and the presence of a SARS-CoV-2 infection (p < 0.05) were associated with strong SEs after the BNT162b2 vaccine second dose. Having a history of allergies and a female sex (p < 0.01) were associated with strong SEs after the ChAdOx1-S vaccine second dose. Furthermore, the results reveal, for the first time, the associations between having a history of allergies, chronic diseases, medication usage, and SEs of a strong magnitude for the BNT162b2 and ChAdOx1-S vaccines. Additionally, this study supports the association of the female sex and infection with SARS-CoV-2 with an increased potential of developing stronger SEs with certain anti-SARS-CoV-2 vaccines.
Reference47 articles.
1. Shao, N., Zhang, C., Dong, J., Sun, L., Chen, X., Xie, Z., Xu, B., An, S., Zhang, T., and Yang, F. (2022). Molecular evolution of human coronavirus-NL63, -229E, -HKU1 and -OC43 in hospitalized children in China. Front. Microbiol., 13. 2. WHO (2022). Statement for Healthcare Professionals: How COVID-19 Vaccines Are Regulated for Safety and Effectiveness (Revised March 2022), WHO. 3. COVID-19: Hospital admissions rise in England amid fears of new variant and waning immunity;Looi;BMJ,2023 4. Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety;Mascellino;Infect. Drug Resist.,2021 5. Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans;Dickerman;N. Engl. J. Med.,2022
|
|